The Interventional Pharmacoeconomic Toolbox Panel Discussion

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Oct

Today In Oncology

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Related Videos

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Revumenib Approved by FDA for NPM1 AML

FDA Approves Belantamab Mafodotin for Relapsed or Refractory Multiple Myeloma

Metastatic ER-Positive HER2-Negative Breast Cancer Novel Treatment Combination Improves Progression-Free Survival

Final FLAURA2 Analysis Confirms First-Line Benefit of Osimertinib-Chemotherapy in EGFR-Positive NSCLC

Thymic Health Associated With ICI Response